BLOOD CANCER UNITED INC: Form 990, tax year 2015
View the entire original 990 at ProPublica ↗
- Organization
- BLOOD CANCER UNITED INC (EIN 13-5644916)
- Tax period
- 2015-07-01 to 2016-06-30
- Filed
- 2017-02-06
- IRS object ID
- 201740379349300204
- Schema version
- 2015v3.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2017-02-06T08:41:48-05:00 | ReturnTs |
| Tax Period End | 2016-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 135565207 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 345 PARK AVENUE | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 101540102 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2015-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 135644916 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE LEUKEMIA & LYMPHOMA SOCIETYINC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | LEUK | BusinessNameControlTxt |
| Phone | 9149495213 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3 INTERNATIONAL DRIVE | AddressLine1Txt |
| City | RYE BROOK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10573 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | ROSEMARIE A LOFFREDO | PersonNm |
| Person Title | EVP - CAO & CFO | PersonTitleTxt |
| Phone | 9148218877 | PhoneNum |
| Signature | 2017-01-30 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | DAVID M HIGHFILL | PreparerPersonNm |
| PTIN | P01517891 | PTIN |
| Phone | 2127589700 | PhoneNum |
| Preparation | 2017-01-30 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2015 | TaxYr |
| Build TS | 2021-01-29 14:40:06Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Change | Yes (X) | AddressChangeInd |
| Principal Officer | LOUIS J DEGENNARO | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3 INTERNATIONAL DRIVE SUITE 200 | AddressLine1Txt |
| City | RYE BROOK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10573 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $509,381,899 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.LLS.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1949 | FormationYr |
| Legal Domicile State | NY | LegalDomicileStateCd |
| Activity Or Mission | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. | ActivityOrMissionDesc |
| Voting Members Governing Body | 28 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 28 | VotingMembersIndependentCnt |
| Total Employee | 1455 | TotalEmployeeCnt |
| Total Volunteers | 3000000 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $283,909,984 | PYContributionsGrantsAmt |
| CY Contributions Grants | $285,638,088 | CYContributionsGrantsAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $4,913,321 | PYInvestmentIncomeAmt |
| CY Investment Income | -$6,187,940 | CYInvestmentIncomeAmt |
| PY Other Revenue | -$7,194,375 | PYOtherRevenueAmt |
| CY Other Revenue | -$7,722,874 | CYOtherRevenueAmt |
| PY Total Revenue | $281,628,930 | PYTotalRevenueAmt |
| CY Total Revenue | $271,727,274 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $107,996,054 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $88,538,361 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $85,679,493 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $87,185,045 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $4,709,809 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $4,059,876 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $35,316,836 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $79,057,701 | PYOtherExpensesAmt |
| CY Other Expenses | $74,986,029 | CYOtherExpensesAmt |
| PY Total Expenses | $277,443,057 | PYTotalExpensesAmt |
| CY Total Expenses | $254,769,311 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $4,185,873 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $16,957,963 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $214,485,806 | TotalAssetsBOYAmt |
| Total Assets EOY | $217,192,867 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $116,963,860 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $99,112,566 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $97,521,946 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $118,080,301 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $52,234,348 | ExpenseAmt |
| Grant | $47,209,977 | GrantAmt |
| Desc | A) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2016, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 5 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 47 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2016, FOR THE FIFTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-T | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $85,232,201 | ExpenseAmt |
| Grant | $41,328,384 | GrantAmt |
| Desc | B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.24 MILLION PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION; PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. - 615,479 FREE PRINTED DISEASE AND SUPPORT BOOKLETS, 5,498 DISEASE-FOCUSED FACT SHEETS, AND 141 DVDS WERE ORDERED IN 2016. FINANCIAL ASSISTANCE IN 2016, A COMBINED 40,835,972 WAS DISBURSED TO PATIENTS THROUGH THE CO-PAY ASSISTANCE PROGRAMS (40,029,645) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM, (793,500), AND LLS FINANCIAL ASSISTANCE PROGRAM (12,827). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2016, 40,029,645 WAS PROVIDED TO PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. - 18,155 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2016. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2016, 793,500 WAS PROVIDED TO PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM 1,587 PATIENTS RECEIVED LLS TRAVEL ASSISTANCE IN 2016 FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS (PCR PROGRAM) THE FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS SUPPORTS QUALIFYING PATIENTS WITH OUT OF POCKET EXPENSES RELATED TO THEIR ROUTINE POLYMERASE CHAIN REACTION (PCR) EXAM. IN 2016, 12,827 WAS PROVIDED TO PATIENTS THROUGH THE PCR PROGRAM 260 PATIENTS RECEIVED LLS PCR ASSISTANCE IN 2016 COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY STAFF (PATIENT ACCESS MANAGERS) AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. LOCAL PATIENT EDUCATION PROGRAMS: IN FY 2016 WE CONDUCTED 43 LOCAL PATIENT EDUCATION PROGRAMS TO 1,893 ATTENDEES. THIRTY-SIX WERE PROGRAMS THAT COVERED DISEASE SPECIFIC TOPICS, SURVIVORSHIP ISSUES, AND/OR EDUCATION ABOUT CANCER CLINICAL TRIALS AND MAKING TREATMENT DECISIONS. OF THESE 36, 12 WERE LOCATED IN AND WERE SPECIFICALLY TAILORED TO UNDERSERVED COMMUNITIES, ESPECIALLY RACIAL AND ETHNIC MINORITY GROUPS AND OLDER ADULTS. SEVEN PROGRAMS WERE FOCUSED ON THE DIAGNOSIS AND TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS OR MPN. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2016, 16 BCC CONFERENCES WERE HELD WITH 4,805 ATTENDEES LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2016, THERE WERE APPROXIMATELY 2,500 COMMUNITY MEMBERS AND 15,000 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 4,000 COMMENTS POSTED BY USERS FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2016, LLS SUPPORTED OR HOSTED 204 REGISTERED FAMILY SUPPORT GROUP MEETINGS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -717 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2016. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $40,255,829 | ExpenseAmt |
| Desc | C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS ALSO CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. THE INFORMATION RESOURCE CENTER ALSO HAS AN EXPANDING IN-DEPTH CLINICAL TRIAL NAVIGATION SERVICE. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2016: - 26,668 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 12,399 UNIQUE INDIVIDUALS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -167 PATIENTS WORKED WITH A CLINICAL TRIAL NAVIGATOR TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; 49% OF THESE PATIENTS ENROLLED ON A CLINICAL TRIAL. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, DISCUSSION BOARDS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. INFORMATIONAL MATERIALS ARE AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. MANY DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS ADDITIONALLY, LLS ALSO SPONSORS TELEPHONE- WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. IN FY 2016: -20,906 INDIVIDUALS PARTICIPATED IN LLS'S ONLINE DISCUSSION BOARDS -LLS PROVIDED 9 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 3,032 PARTICIPANTS -THERE WERE 24,078 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 16,612 VIEWS OF VIDEOS. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $15,384,710 | ExpenseAmt |
| Desc | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $15,384,710 | TotalOtherProgSrvcExpenseAmt |
| Total Program Service Expenses | $193,107,088 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (true) | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | Yes (true) | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Temp Or Permanent Endowments | Yes (true) | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | Yes (true) | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (true) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | false | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (true) | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | Yes (true) | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (true) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (true) | FundraisingActivitiesInd |
| Gaming Activities | Yes (true) | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (true) | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | false | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (true) | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | Yes (true) | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (true) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (true) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| IRP Document | 614 | IRPDocumentCnt |
| IRP Document W2 G | 8 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 1455 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (true) | ForeignFinancialAccountInd |
| Foreign Country | CA | ForeignCountryCd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (true) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (true) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 28 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 28 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (true) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (true) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | Yes (true) | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | Yes (true) | LocalChaptersInd |
| Policies Reference Chapters | Yes (true) | PoliciesReferenceChaptersInd |
| Form990 Provided To Gvrn Body | Yes (true) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AZ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DE | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ID | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | LA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NE | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | ROSEMARIE A LOFFREDO | PersonNm |
| Phone | 9149495213 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3 INTERNATIONAL DRIVE | AddressLine1Txt |
| City | RYE BROOK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10573 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (42 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd |
|---|---|---|---|---|---|---|---|---|---|---|
| LOUIS J DEGENNARO | ||||||||||
| PRESIDENT & | 40.00 | 1.00 | Yes (X) | $511,049 | $0 | $55,178 | ||||
| ROSEMARIE A LOFFREDO | ||||||||||
| EVP - CAO & | 40.00 | 1.00 | Yes (X) | $325,143 | $0 | $26,556 | ||||
| GORDON MILLER JR | ||||||||||
| SVP FINANCE | 40.00 | 5.00 | Yes (X) | $257,007 | $0 | $44,252 | ||||
| MARK ROITHMAYR | ||||||||||
| EVP CHIEF RE | 40.00 | $360,544 | $0 | $47,654 | Yes (X) | |||||
| ANDREW S COCCARI | ||||||||||
| EVP CHIEF PR | 40.00 | $151,419 | $0 | $26,842 | Yes (X) | |||||
| CLAUDE E EDKINS | ||||||||||
| SVP CHIEF IN | 40.00 | 1.00 | $308,347 | $0 | $38,125 | Yes (X) | ||||
| LEE M GREENBERGER | ||||||||||
| SVP CHIEF SC | 40.00 | $288,435 | $0 | $42,797 | Yes (X) | |||||
| NANCY HALLBERG | ||||||||||
| SVP CHIEF MA | 40.00 | $226,725 | $0 | $26,797 | Yes (X) | |||||
| JAMES A MASSARA | ||||||||||
| VP APP & TRA | 40.00 | $224,952 | $0 | $35,176 | Yes (X) | |||||
| OSMAN MAZHAR | ||||||||||
| VP PLATFORM | 40.00 | $223,521 | $0 | $34,694 | Yes (X) | |||||
| JEFFREY COMO-TERM DEC2014 | ||||||||||
| CHIEF INFORM | 40.00 | $130,452 | $0 | $0 | Yes (X) | |||||
| GEORGE J OMIROS-TERM APR15 | ||||||||||
| EVP-CHIEF CA | 40.00 | $485,575 | $0 | $9,898 | Yes (X) | |||||
| GABRIELLE URQUHART-TERM JUN15 | ||||||||||
| REGIONAL VP | 40.00 | $186,726 | $0 | $10,666 | Yes (X) | |||||
| JOHN E WALTER - TERM FEB14 | ||||||||||
| PRESIDENT & | 0.00 | $146,327 | $0 | $0 | Yes (X) | |||||
| JAMES H DAVIS PHD | ||||||||||
| CHAIR | 6.00 | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| ELIZABETH J CLARK PHD | ||||||||||
| VICE CHAIR | 4.00 | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| PETER B BROCK | ||||||||||
| SECRETARY/TR | 4.00 | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| DONALD PROCTOR | ||||||||||
| AT-LARGE | 4.00 | 2.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| JAMES A BECK | ||||||||||
| BOD MEMBER | 4.00 | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| WILLIAM G BEHNKE | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| JORGE L BENITEZ | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| JAMES E BRADNER | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| A DANA CALLOW JR | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| SCOTT A CARROLL | ||||||||||
| BOD MEMBER | 4.00 | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| WILLIAM S DALTON PHD | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| GRACIELA E ELETA | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| BERNARD H GARIL | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| FRANCIE HELLER | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| RAANAN HOROWITZ | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| RICHARD M JEANNERET | ||||||||||
| BOD MEMBER | 4.00 | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| JOSEPH B KELLEY | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| RALPH E LAWSON | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| MICHELLE LE BEAU PHD | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| GILLES LEGAULT | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| CONNIE LINDSEY | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| STEVEN T ROSEN | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| KENNETH M SCHWARTZ | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| BART SICHEL | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| FRANK O SMITH | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| KATHRYN C VECELLIO | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| LOUISE G WARNER | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| KEITH S WHITE | ||||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | |||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,826,222 | TotalReportableCompFromOrgAmt |
| Total Other Compensation | $398,635 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 147 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | Yes (true) | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| OLIVER STAFFING INC | |||||
| 350 LEXINGTON AV SUITE 401 | NEW YORK | NY | 10016 | TEMP STAFFING | $5,017,393 |
| RESOURCE ONE | |||||
| 2900 EAST APACHE STREET | TULSA | OK | 74110 | DIRECT MARKETIN | $4,153,198 |
| APPIRIO INC | |||||
| PO BOX 123011 | DALLAS | TX | 75312 | IT SOFTWARE DEV | $3,696,159 |
| PATIENT ADVOCACY FOUNDATION | |||||
| 421 BUTLER FARM RD | HAMPTON | VA | 23666 | PAT ASSIST PROC | $3,378,284 |
| RESOLUTE MEDIA LLC | |||||
| 137 W 25TH ST | NEW YORK | NY | 10001 | DIGITAL MARKETI | $2,824,015 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 116 | CntrctRcvdGreaterThan100KCnt |
| Federated Campaigns | $1,784,943 | FederatedCampaignsAmt |
| Fundraising | $165,077,259 | FundraisingAmt |
| All Other Contributions | $118,775,886 | AllOtherContributionsAmt |
| Noncash Contributions | $1,349,813 | NoncashContributionsAmt |
| Total Contributions | $285,638,088 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,480,895 | TotalRevenueColumnAmt |
| Exclusion | $1,480,895 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $84,951 | TotalRevenueColumnAmt |
| Exclusion | $84,951 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $204,044,790 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $211,713,625 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | -$7,668,835 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$7,668,835 | TotalRevenueColumnAmt |
| Exclusion | -$7,668,835 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $17,468,116 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $165,077,259 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $25,748,962 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$8,280,846 | TotalRevenueColumnAmt |
| Exclusion | -$8,280,846 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gaming Gross Income | $645,530 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $192,038 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $453,492 | TotalRevenueColumnAmt |
| Exclusion | $453,492 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | OTHER MISCELLANEOUS | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $19,529 | TotalRevenueColumnAmt |
| Exclusion | $19,529 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $19,529 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $271,727,274 | TotalRevenueColumnAmt |
| Exclusion | -$13,910,814 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $42,665,209 | TotalAmt |
| Program Services | $42,665,209 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $41,328,384 | TotalAmt |
| Program Services | $41,328,384 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,544,768 | TotalAmt |
| Program Services | $4,544,768 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,928,334 | TotalAmt |
| Program Services | $1,313,608 | ProgramServicesAmt |
| Management And General | $354,326 | ManagementAndGeneralAmt |
| Fundraising | $260,400 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $69,382,376 | TotalAmt |
| Program Services | $47,258,757 | ProgramServicesAmt |
| Management And General | $12,746,230 | ManagementAndGeneralAmt |
| Fundraising | $9,377,389 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,752,493 | TotalAmt |
| Program Services | $1,137,472 | ProgramServicesAmt |
| Management And General | $295,027 | ManagementAndGeneralAmt |
| Fundraising | $319,994 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $9,064,877 | TotalAmt |
| Program Services | $5,883,642 | ProgramServicesAmt |
| Management And General | $1,526,046 | ManagementAndGeneralAmt |
| Fundraising | $1,655,189 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,056,965 | TotalAmt |
| Program Services | $3,282,269 | ProgramServicesAmt |
| Management And General | $851,326 | ManagementAndGeneralAmt |
| Fundraising | $923,370 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $799,353 | TotalAmt |
| Program Services | $526,011 | ProgramServicesAmt |
| Management And General | $108,064 | ManagementAndGeneralAmt |
| Fundraising | $165,278 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $235,061 | TotalAmt |
| Program Services | $154,681 | ProgramServicesAmt |
| Management And General | $31,778 | ManagementAndGeneralAmt |
| Fundraising | $48,602 | FundraisingAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $858,819 | TotalAmt |
| Program Services | $565,143 | ProgramServicesAmt |
| Management And General | $116,103 | ManagementAndGeneralAmt |
| Fundraising | $177,573 | FundraisingAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,059,876 | TotalAmt |
| Fundraising | $4,059,876 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $190,962 | TotalAmt |
| Program Services | $125,663 | ProgramServicesAmt |
| Management And General | $25,816 | ManagementAndGeneralAmt |
| Fundraising | $39,483 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,276,467 | TotalAmt |
| Program Services | $9,394,577 | ProgramServicesAmt |
| Management And General | $1,930,024 | ManagementAndGeneralAmt |
| Fundraising | $2,951,866 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,184,624 | TotalAmt |
| Program Services | $2,964,761 | ProgramServicesAmt |
| Management And General | $816,170 | ManagementAndGeneralAmt |
| Fundraising | $2,403,693 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $18,094,538 | TotalAmt |
| Program Services | $9,531,800 | ProgramServicesAmt |
| Management And General | $1,979,838 | ManagementAndGeneralAmt |
| Fundraising | $6,582,900 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,313,585 | TotalAmt |
| Program Services | $4,154,632 | ProgramServicesAmt |
| Management And General | $853,528 | ManagementAndGeneralAmt |
| Fundraising | $1,305,425 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,874,288 | TotalAmt |
| Program Services | $6,029,595 | ProgramServicesAmt |
| Management And General | $1,242,672 | ManagementAndGeneralAmt |
| Fundraising | $1,602,021 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,296,935 | TotalAmt |
| Program Services | $4,747,531 | ProgramServicesAmt |
| Management And General | $1,258,507 | ManagementAndGeneralAmt |
| Fundraising | $1,290,897 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,399,479 | TotalAmt |
| Program Services | $4,135,437 | ProgramServicesAmt |
| Management And General | $1,057,956 | ManagementAndGeneralAmt |
| Fundraising | $1,206,086 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $596,750 | TotalAmt |
| Program Services | $292,444 | ProgramServicesAmt |
| Management And General | $266,608 | ManagementAndGeneralAmt |
| Fundraising | $37,698 | FundraisingAmt |
Other Expenses OtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | MISCELLANEOUS | Desc |
| Total | $4,865,168 | TotalAmt |
| Program Services | $3,070,704 | ProgramServicesAmt |
| Management And General | $885,368 | ManagementAndGeneralAmt |
| Fundraising | $909,096 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $254,769,311 | TotalAmt |
| Program Services | $193,107,088 | ProgramServicesAmt |
| Management And General | $26,345,387 | ManagementAndGeneralAmt |
| Fundraising | $35,316,836 | FundraisingAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | Yes (X) | JointCostsInd |
Total Joint Costs TotalJointCostsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,780,749 | TotalAmt |
| Program Services | $5,786,717 | ProgramServicesAmt |
| Fundraising | $5,994,032 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,141,619 | BOYAmt |
| EOY | $14,966,805 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $42,601,449 | BOYAmt |
| EOY | $58,353,033 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,633,988 | BOYAmt |
| EOY | $16,707,733 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,813,918 | BOYAmt |
| EOY | $2,768,847 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $43,265,070 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $26,528,369 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $14,702,511 | BOYAmt |
| EOY | $16,736,701 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $86,639,070 | BOYAmt |
| EOY | $96,515,546 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $48,953,251 | BOYAmt |
| EOY | $11,144,202 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $214,485,806 | BOYAmt |
| EOY | $217,192,867 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $17,799,196 | BOYAmt |
| EOY | $14,820,632 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $81,859,872 | BOYAmt |
| EOY | $71,699,343 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $17,304,792 | BOYAmt |
| EOY | $12,592,591 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $116,963,860 | BOYAmt |
| EOY | $99,112,566 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $71,640,456 | BOYAmt |
| EOY | $82,002,442 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $22,847,577 | BOYAmt |
| EOY | $32,998,850 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,033,913 | BOYAmt |
| EOY | $3,079,009 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $97,521,946 | BOYAmt |
| EOY | $118,080,301 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $214,485,806 | BOYAmt |
| EOY | $217,192,867 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $16,957,963 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $3,584,815 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $15,577 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | false | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $282,672,072 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $279,789,664 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $302,437,152 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $283,909,984 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $285,638,088 | CurrentTaxYearAmt |
| Total | $1,434,446,960 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $282,672,072 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $279,789,664 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $302,437,152 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $283,909,984 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $285,638,088 | CurrentTaxYearAmt |
| Total | $1,434,446,960 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $213,124,363 | SubstantialContributorsTotAmt |
| Public Support Total170 | $1,221,322,597 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $2,705,046 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,260,636 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,203,865 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,891,412 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,565,846 | CurrentTaxYearAmt |
| Total | $9,626,805 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,502,044 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,974,227 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $104,879 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $56,829 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $19,529 | CurrentTaxYearAmt |
| Total | $3,657,508 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $1,447,731,273 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $134,627,972 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.84360 | PublicSupportCY170Pct |
| Public Support PY170 | 0.83340 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II, LINE 10 | FormAndLineReferenceDesc |
| Explanation | GRANT TERM. & REFUND (YR 2011,2012) 3,321,237 OTHER MISC. REVENUE (YR 2011-2015) 336,271 | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | Yes (true) | VolunteersInd |
| Paid Staff Or Management | Yes (true) | PaidStaffOrManagementInd |
| Media Advertisements | false | MediaAdvertisementsInd |
| Mailings Members | false | MailingsMembersInd |
| Publications Or Broadcast | Yes (true) | PublicationsOrBroadcastInd |
| Publications Or Broadcast | $157,886 | PublicationsOrBroadcastAmt |
| Grants Other Organizations | false | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | Yes (true) | DirectContactLegislatorsInd |
| Direct Contact Legislators | $125,505 | DirectContactLegislatorsAmt |
| Rallies Demonstrations | Yes (true) | RalliesDemonstrationsInd |
| Rallies Demonstrations | $157,031 | RalliesDemonstrationsAmt |
| Other Activities | Yes (true) | OtherActivitiesInd |
| Other Activities | $418,397 | OtherActivitiesAmt |
| Total Lobbying Expenditures | $858,819 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | false | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE C, PART II-B, LINE 1 | LLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. |
| SCHEDULE C, PART IV | LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT- ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA. |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Collection Used Pub Exhibition | Yes (X) | CollectionUsedPubExhibitionInd |
| Solicited Assets Sale | false | SolicitedAssetsSaleInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,115,645 | BeginningYearBalanceAmt |
| Contributions | $45,095 | ContributionsAmt |
| Investment Earnings Or Losses | $116,288 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$240,000 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$9,060 | AdministrativeExpensesAmt |
| End Year Balance | $6,027,967 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,122,698 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $218,549 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$221,499 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$4,103 | AdministrativeExpensesAmt |
| End Year Balance | $6,115,645 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,027,657 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $313,872 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$215,000 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$3,831 | AdministrativeExpensesAmt |
| End Year Balance | $6,122,698 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,000,186 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $482,520 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$450,000 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$5,049 | AdministrativeExpensesAmt |
| End Year Balance | $6,027,657 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,059,994 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $48,916 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | -$9,992 | AdministrativeExpensesAmt |
| End Year Balance | $6,000,186 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Prmnnt Endowment Balance EOY | 0.51000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.49000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | false | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | false | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,211,251 | OtherCostOrOtherBasisAmt |
| Depreciation | $634,183 | DepreciationAmt |
| Book Value | $577,068 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $38,235,970 | OtherCostOrOtherBasisAmt |
| Depreciation | $22,872,576 | DepreciationAmt |
| Book Value | $15,363,394 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $3,817,849 | OtherCostOrOtherBasisAmt |
| Depreciation | $3,021,610 | DepreciationAmt |
| Book Value | $796,239 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $16,736,701 | TotalBookValueLandBuildingsAmt |
Other Securities OtherSecuritiesGrp (3 entries)
| DescDesc | Book ValueBookValueAmt | Method ValuationMethodValuationCd |
|---|---|---|
| FUND OF HEDGE FUNDS- OPERATING | $9,739,180 | F |
| 457B PLAN | $1,405,022 | F |
| FUND OF HEDGE FUNDS-ENDOWMENT | F |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Securities | $11,144,202 | TotalBookValueSecuritiesAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $295,737,491 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $3,584,815 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $11,174,900 | DonatedServicesAndUseFcltsAmt |
| Other Revenue | $9,461,935 | OtherRevenueAmt |
| Revenue Not Reported | $24,221,650 | RevenueNotReportedAmt |
| Revenue Subtotal | $271,515,841 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $190,961 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | $20,472 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $211,433 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $271,727,274 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $274,565,927 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $11,174,900 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $8,702,677 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $19,877,577 | ExpensesNotReportedAmt |
| Expenses Subtotal | $254,688,350 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $190,961 | InvestmentExpensesNotIncld2Amt |
| Other Expenses Not Included | -$110,000 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $80,961 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $254,769,311 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE D, PAGE 2, PART III, LINE 4 | THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. |
| SCHEDULE D, PAGE 2, PART V, LINE 4 | LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. |
| SCHEDULE D, PAGE 3, PART X | LLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2016 AND 2015. |
| SCHEDULE D, PAGE 4, PART XI, LINE 2D | LLS CANADA REVENUE 8,899,624 PEARPOINT CANCER SUPPORT REVENUE 10,311 NET ASSETS TRANSFER 552,000 |
| SCHEDULE D, PAGE 4, PART XI, LINE 4B | PEARPOINT MANAGEMENT FEES 20,472 |
| SCHEDULE D, PAGE 4, PART XII, LINE 2D | LLS CANADA EXPENSES 8,653,353 PEARPOINT CANCER SUPPORT EXPENSES 49,324 |
| SCHEDULE D, PAGE 4, PART XII, LINE 4B | LLS CANADA FOREIGN CURRENCY ADJ -110,000 |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (5 entries)
| RegionRegionTxt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt | OfficesOfficesCnt |
|---|---|---|---|---|---|
| CENTRAL AMERICA & CARIBBEAN | 2 | INVESTMENTS | INVESTMENTS | $5,734,913 | |
| EAST ASIA | 3 | RESEARCH FUNDING | RESEARCH GRANTS | $1,940,000 | |
| NORTH AMERICA | 5 | RESEARCH FUNDING | RESEARCH GRANTS | $1,064,385 | 7 |
| EUROPE | 8 | RESEARCH FUNDING | RESEARCH GRANTS | $1,540,383 | |
| EUROPE | 1 | INVESTMENTS | INVESTMENTS | $1,225,325 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 7 | SubtotalOfficesCnt |
| Subtotal Employees | 19 | SubtotalEmployeesCnt |
| Total Office | 7 | TotalOfficeCnt |
| Total Employee | 19 | TotalEmployeeCnt |
| Subtotal Spent | $11,505,006 | SubtotalSpentAmt |
| Total Spent | $11,505,006 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (17 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Valuation Method UsedValuationMethodUsedDesc |
|---|---|---|---|---|
| EAST ASIA & PACIFIC | RESEARCH GRANTS | $1,250,000 | CHECK | FMV |
| EAST ASIA & PACIFIC | RESEARCH GRANTS | $100,000 | CHECK | FMV |
| EAST ASIA & PACIFIC | RESEARCH GRANTS | $200,000 | CHECK | FMV |
| EUROPE | RESEARCH GRANTS | $65,583 | CHECK | FMV |
| EUROPE | RESEARCH GRANTS | $110,000 | CHECK | FMV |
| EUROPE | RESEARCH GRANTS | $200,000 | WIRE | FMV |
| EUROPE | RESEARCH GRANTS | $199,800 | WIRE | FMV |
| EUROPE | RESEARCH GRANTS | $200,000 | WIRE | FMV |
| EUROPE | RESEARCH GRANTS | $65,000 | WIRE | FMV |
| EUROPE | RESEARCH GRANTS | $200,000 | WIRE | FMV |
| EUROPE | THERAPY ACCELERATION | $500,000 | WIRE | FMV |
| NORTH AMERICA | RESEARCH GRANTS | $200,000 | WIRE | FMV |
| NORTH AMERICA | RESEARCH GRANTS | $200,000 | CHECK | FMV |
| NORTH AMERICA | RESEARCH GRANTS | $199,980 | WIRE | FMV |
| NORTH AMERICA | RESEARCH GRANTS | $65,000 | CHECK | FMV |
| EAST ASIA & PACIFIC | RESEARCH GRANT | $390,000 | CHECK | FMV |
| NORTH AMERICA | RESEARCH GRANT | $399,405 | CHECK | FMV |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 17 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (true) | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (true) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | Yes (true) | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE F, PAGE 1, PART I, LINE 2 | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. |
| SCHEDULE F, PAGE 1, PART I, LINE 3 | CENTRAL AMERICA & CARIBBEAN 0 5,734,913 EAST ASIA 1,940,000 0 NORTH AMERICA 1,064,385 0 EUROPE 1,540,383 0 EUROPE 0 1,225,325 |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| Phone Solicitations | Yes (X) | PhoneSolicitationsInd |
| In Person Solicitations | Yes (X) | InPersonSolicitationsInd |
| Solicitation Of Non Govt Grants | Yes (X) | SolicitationOfNonGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (true) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp (6 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | ActivityActivityTxt | Fundraiser Control Of FundsFundraiserControlOfFundsInd | Retained By ContractorRetainedByContractorAmt | Net To OrganizationNetToOrganizationAmt |
|---|---|---|---|---|---|---|---|
| MAIL AMERICA COMMUNICATIONS INC | |||||||
| 174 ELKTON FARM ROAD | FOREST | VA | 24551 | DIRECT MAI | false | $1,642,126 | -$1,642,126 |
| THOMPSON HABIB & DENISON | |||||||
| 80 HAYDEN AVENUE SUITE 300 | LEXINGTON | MA | 02421 | DIRECT MAI | false | $456,932 | -$456,932 |
| COINSTAR | |||||||
| 1800 114TH AVENUE SE | BELLEVUE | WA | 98004 | COIN COLLE | false | $407,239 | -$407,239 |
| DONOR CARE CENTER INC | |||||||
| 4345 STRAUSSSER ST NW | NORTH CANTON | OH | 44720 | TELEMARKET | false | $194,253 | -$194,253 |
| THE HERITAGE COMPANY INC | |||||||
| PO BOX 16325 | LITTLE ROCK | AR | 722316325 | DIRECT MAI | false | $70,917 | -$70,917 |
| INFOCISION MANAGEMENT CORPORATION | |||||||
| 325 SPRINSIDE DRIVE | AKRON | OH | 44333 | TELEMARKET | false | $54,276 | -$54,276 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Retained By Contractors | $2,825,743 | TotalRetainedByContractorsAmt |
| Total Net To Organization | -$2,825,743 | TotalNetToOrganizationAmt |
| All States | All States | AllStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | LAKE TAHOE BIKE | Event1Nm |
| Gross Receipts Event1 | $3,450,905 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $3,222,877 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $228,028 | GrossRevenueEvent1Amt |
| Non Cash Prizes Event1 | $65,572 | NonCashPrizesEvent1Amt |
| Rent Facility Costs Event1 | $211 | RentFacilityCostsEvent1Amt |
| Food And Beverage Event1 | $53,932 | FoodAndBeverageEvent1Amt |
| Entertainment Event1 | $5 | EntertainmentEvent1Amt |
| Other Direct Expenses Event1 | $444,194 | OtherDirectExpensesEvent1Amt |
| Event2 | DC LEUKEMIA BAL | Event2Nm |
| Gross Receipts Event2 | $3,083,245 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $1,967,862 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $1,115,383 | GrossRevenueEvent2Amt |
| Non Cash Prizes Event2 | $6,912 | NonCashPrizesEvent2Amt |
| Rent Facility Costs Event2 | $561,055 | RentFacilityCostsEvent2Amt |
| Food And Beverage Event2 | $325,015 | FoodAndBeverageEvent2Amt |
| Entertainment Event2 | $272,400 | EntertainmentEvent2Amt |
| Other Direct Expenses Event2 | $6,323 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 518 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $176,011,225 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $159,886,520 | CharitableContriOtherEventsAmt |
| Gross Revenue Other Events | $16,124,705 | GrossRevenueOtherEventsAmt |
| Non Cash Prizes Other Events | $4,511,145 | NonCashPrizesOtherEventsAmt |
| Rent Fclty Costs Other Events | $6,832,313 | RentFcltyCostsOtherEventsAmt |
| Food And Beverage Other Events | $3,296,541 | FoodAndBeverageOtherEventsAmt |
| Entertainment Other Events | $440,177 | EntertainmentOtherEventsAmt |
| Oth Direct Expnss Other Events | $8,933,167 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $182,545,375 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $165,077,259 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $17,468,116 | GrossRevenueTotalEventsAmt |
| Non Cash Prizes Total Events | $4,583,629 | NonCashPrizesTotalEventsAmt |
| Rent Fclty Costs Total Events | $7,393,579 | RentFcltyCostsTotalEventsAmt |
| Food And Beverage Total Events | $3,675,488 | FoodAndBeverageTotalEventsAmt |
| Entertainment Total Events | $712,582 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $9,383,684 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $25,748,962 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$8,280,846 | NetIncomeSummaryAmt |
Gaming Information GamingInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteer Labor Bingo | false | VolunteerLaborBingoInd |
| Volunteer Labor Pull Tabs | false | VolunteerLaborPullTabsInd |
| Gross Revenue Other Gaming | $645,530 | GrossRevenueOtherGamingAmt |
| Cash Prizes Other Gaming | $2,380 | CashPrizesOtherGamingAmt |
| Non Cash Prizes Other Gaming | $179,806 | NonCashPrizesOtherGamingAmt |
| Oth Direct Expnss Other Gaming | $9,852 | OthDirectExpnssOtherGamingAmt |
| Volunteer Labor Other Gaming | Yes (true) | VolunteerLaborOtherGamingInd |
| Volunteer Labor Other Gaming | 0.90000 | VolunteerLaborOtherGamingPct |
| Gross Revenue Total Gaming | $645,530 | GrossRevenueTotalGamingAmt |
| Cash Prizes Total Gaming | $2,380 | CashPrizesTotalGamingAmt |
| Non Cash Prizes Total Gaming | $179,806 | NonCashPrizesTotalGamingAmt |
| Oth Direct Expnss Total Gaming | $9,852 | OthDirectExpnssTotalGamingAmt |
| Direct Expense Summary Gaming | $192,038 | DirectExpenseSummaryGamingAmt |
| Net Gaming Income Summary | $453,492 | NetGamingIncomeSummaryAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| States Where Gaming Conducted | AL | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | DE | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | DC | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | NY | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | OH | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | OR | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | PA | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | TX | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | IA | StatesWhereGamingConductedCd |
| Licensed | Yes (true) | LicensedInd |
| License Suspended Etc | false | LicenseSuspendedEtcInd |
| Gaming With Nonmembers | false | GamingWithNonmembersInd |
| Member Of Other Entity | false | MemberOfOtherEntityInd |
| Gaming Own Facility | 0.25000 | GamingOwnFacilityPct |
| Gaming Other Facility | 0.75000 | GamingOtherFacilityPct |
| Individual With Books | ROSEMARIE LOFFREDO | IndividualWithBooksNm |
Persons With Books US Address PersonsWithBooksUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3 INTERNATIONAL DRIVE SUITE 200 | AddressLine1Txt |
| City | RYE BROOK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10573 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct With3rd Prty For Game Rev | false | CntrctWith3rdPrtyForGameRevInd |
| Gaming Manager Person | SEE SCHEDULE G PART IV | GamingManagerPersonNm |
| Charitable Distribution Rqr | false | CharitableDistributionRqrInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE G, PAGE 2, PART III, LINE 9 | TEXAS, IOWA |
| SCHEDULE G, PART IV | SCHEDULE G PART I, LINE 2B LLS USED MAIL AMERICA COMMUNICATIONS AND THOMPSON, HABIG & DENSION FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 19,208,525 DURING FISCAL YEAR 2016. LLS USED INFOCISION MANAGEMENT CORPORATION, COINSTAR AND DONOR CARE CENTER FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING THE FISCAL YEAR 2016. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF THE FAIR MARKET VALUE OF BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 16 THE LEUKEMIA AND LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF. |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (236 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | Cash GrantCashGrantAmt | Valuation Method UsedValuationMethodUsedDesc | Purpose Of GrantPurposeOfGrantTxt | IRC SectionIRCSectionDesc |
|---|---|---|---|---|---|---|---|---|
| ACETYLON PHARMACEUTICALS INC | ||||||||
| SEAPORT CTR 70 FARGO ST SUITE 205 | BOSTON | MA | 022102138 | 263506788 | $1,300,000 | FMV | THERAPY ACCELERATION | |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE BELFER 1108 | BRONX | NY | 10471 | 472209056 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE BELFER 1108 | BRONX | NY | 10471 | 472209056 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE BELFER 1108 | BRONX | NY | 10471 | 472209056 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE BELFER 1108 | BRONX | NY | 10471 | 472209056 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE BELFER 1108 | BRONX | NY | 10471 | 472209056 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||||
| 1300 MORRIS PARK AVE BELFER 1108 | BRONX | NY | 10471 | 472209056 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ARIZONA BOARD OF REGENTS UNIVERSIT | ||||||||
| PO BOX 210158 RM 510 | TUCSON | AZ | 857210158 | 742652689 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| ONE BAYLOR PLAZA MAIL STOP BCM-31 | HOUSTON | TX | 77030 | 741613878 | $1,250,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| ONE BAYLOR PLAZA MAIL STOP BCM-31 | HOUSTON | TX | 77030 | 741613878 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| ONE BAYLOR PLAZA MAIL STOP BCM-31 | HOUSTON | TX | 77030 | 741613878 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BAYLOR COLLEGE OF MEDICINE | ||||||||
| ONE BAYLOR PLAZA MAIL STOP BCM-310 | HOUSTON | TX | 77030 | 741613878 | $100,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BECKMAN RESEARCH INSTIT OF CITY OF | ||||||||
| 1500 DUARTE ROAD | DUARTE | CA | 910103000 | 953432210 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BECKMAN RESEARCH INSTIT OF CITY OF | ||||||||
| 1500 DUARTE ROAD | DUARTE | CA | 910103000 | 953432210 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BETH ISRAEL DEACONESS | ||||||||
| 330 BROOKLINE AVE BR-0259 | BOSTON | MA | 02215 | 042103881 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BETH ISRAEL DEACONESS | ||||||||
| 330 BROOKLINE AVE BR-0259 | BOSTON | MA | 02215 | 042103881 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BETH ISRAEL DEACONESS | ||||||||
| 330 BROOKLINE AVE BR-0259 | BOSTON | MA | 02215 | 042103881 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BOARD OF REGENTS U OF WISCONSIN SYS | ||||||||
| 21 N PARK ST SUITE 6401 | MADISON | WI | 537151218 | 396006492 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BOSTON CHILDREN'S HOSPITAL | ||||||||
| PO BOX 414413 | BOSTON | MA | 022414413 | 042774441 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BOSTON CHILDREN'S HOSPITAL | ||||||||
| PO BOX 414413 | BOSTON | MA | 022414413 | 042774441 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BOSTON CHILDREN'S HOSPITAL | ||||||||
| PO BOX 414413 | BOSTON | MA | 022414413 | 042774441 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BOSTON CHILDREN'S HOSPITAL | ||||||||
| PO BOX 414413 | BOSTON | MA | 022414413 | 042774441 | $133,333 | ACCRUAL | RESEARCH GRANT | 3 |
| BRANDEIS UNIVERSITY | ||||||||
| 415 SOUTH ST | WALTHAM | MA | 02454 | 042103552 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| PO BOX 3149 | BOSTON | MA | 022413149 | 042312909 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| PO BOX 3149 | BOSTON | MA | 022413149 | 042312909 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| PO BOX 3149 | BOSTON | MA | 022413149 | 042312909 | $1,250,000 | ACCRUAL | RESEARCH GRANT | 3 |
| BRIGHAM & WOMENS HOSPITAL | ||||||||
| PO BOX 3149 | BOSTON | MA | 022413149 | 042312909 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CALIFORNIA INSTITUTE OF TECHNOLOGY | ||||||||
| 1200 E CALIFORNIA BLVD MAIL CODE | PASADENA | CA | 91125 | 951643307 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CASE WESTERN RESERVE UNIV SCHOOL OF | ||||||||
| 10900 EUCLID AVENUE | CLEVELAND | OH | 441067037 | 341018992 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CEDARS-SINAI MEDICAL CENTER | ||||||||
| 8700 BEVERLY BOULEVARD 65-WIL 115 | LOS ANGELES | CA | 90048 | 951644600 | $133,333 | ACCRUAL | RESEARCH GRANT | 3 |
| CHILDREN'S HOSPITAL CORPORATION | ||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CHILDREN'S HOSPITAL CORPORATION | ||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CHILDREN'S HOSPITAL LOS ANGELES | ||||||||
| 4650 SUNSET BLVD MAIL STOP 54 | LOS ANGELES | CA | 90027 | 951690977 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CHILDREN'S HOSPITAL LOS ANGELES | ||||||||
| 4650 SUNSET BLVD MAIL STOP 54 | LOS ANGELES | CA | 90027 | 951690977 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CHOP RESEARCH INSTITUTE | ||||||||
| LOCKBOX 1457 PO BOX 8500 | PHILADELPHIA | PA | 191781457 | 231352166 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CINCINNATI CHILDREN'S HOSPITAL MEDI | ||||||||
| 3333 BURNET AVENUE | CINCINATTI | OH | 45229 | 310833936 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CINCINNATI CHILDREN'S RESEARCH FOUN | ||||||||
| 3333 BURNET AVENUE | CINCINNATI | OH | 45229 | 310833936 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CINCINNATI CHILDREN'S RESEARCH FOUN | ||||||||
| 3333 BURNET AVENUE | CINCINNATI | OH | 45229 | 310833936 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| CLEVELAND CLINIC FOUNDATION | ||||||||
| 9500 EUCLID AVENUE | CLEVELAND | OH | 44195 | 340714585 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLD SPRING HARBOR LABORATORY | ||||||||
| 1 BUNGTOWN ROAD PO BOX 100 | COLD SPRING HARBOR | NY | 11724 | 112013303 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET - MAIL CODE 8 | NEW YORK | NY | 10027 | 135598093 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET - MAIL CODE 8 | NEW YORK | NY | 10027 | 135598093 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET - MAIL CODE 8 | NEW YORK | NY | 10027 | 135598093 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET - MAIL CODE 8 | NEW YORK | NY | 10027 | 135598093 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET - MAIL CODE 8 | NEW YORK | NY | 10027 | 135598093 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET - MAIL CODE 8 | NEW YORK | NY | 10027 | 135598093 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET - MAIL CODE 8 | NEW YORK | NY | 10027 | 135598093 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET - MAIL CODE 8 | NEW YORK | NY | 10027 | 135598093 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET | NEW YORK | NY | 10027 | 135598093 | $150,000 | FMV | RESEARCH GRANT | 3 |
| CONSTELLATION PHARMACEUTICALS INC | ||||||||
| 215 FIRST STREET SUITE 200 | CAMBRIDGE | MA | 02142 | 261741721 | $250,000 | FMV | THERAPY ACCELERATION | |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $109,820 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $15,477 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $1,250,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $1,000,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE MAIL STOP BP4 | BOSTON | MA | 02215 | 042263040 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE ROOM M557 | BOSTON | MA | 022155450 | 042263040 | $138,875 | FMV | THERAPY ACCELERATION | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE ROOM M557 | BOSTON | MA | 022155450 | 042263040 | $111,100 | FMV | THERAPY ACCELERATION | 3 |
| DANA-FARBER CANCER INSTITUTE | ||||||||
| 450 BROOKLINE AVENUE ROOM M557 | BOSTON | MA | 022155450 | 042263040 | $55,550 | FMV | THERAPY ACCELERATION | 3 |
| DUKE UNIVERSITY MEDICAL CENTER | ||||||||
| 324 BLACKWLL STREET WASHINGTON BLD | DURHAM | NC | 27708 | 560532129 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| DUKE UNIVERSITY MEDICAL CENTER | ||||||||
| 324 BLACKWLL STREET WASHINGTON BLD | DURHAM | NC | 27708 | 560532129 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| EMORY UNIVERSITY | ||||||||
| 1599 CLIFTON RD NE 4TH FL 1599-0 | ATLANTA | GA | 303224250 | 582137993 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| EMORY UNIVERSITY | ||||||||
| PO BOX 935084 | ATLANTA | GA | 311935084 | 582137993 | $350,000 | FMV | THERAPY ACCELERATION | 3 |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-300 | SEATTLE | WA | 981091024 | 237156071 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-300 | SEATTLE | WA | 981091024 | 237156071 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| FRED HUTCHINSON CANCER RESEARCH CEN | ||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-300 | SEATTLE | WA | 981091024 | 237156071 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT S | ||||||||
| ONE GUSTAVE L LEVY PLACE BOX 350 | NEW YORK | NY | 10029 | 136171197 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT S | ||||||||
| ONE GUSTAVE L LEVY PLACE BOX 350 | NEW YORK | NY | 10029 | 136171197 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT S | ||||||||
| ONE GUSTAVE L LEVY PLACE BOX 350 | NEW YORK | NY | 10029 | 136171197 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT S | ||||||||
| ONE GUSTAVE L LEVY PLACE BOX 350 | NEW YORK | NY | 10029 | 136171197 | $300,000 | ACCRUAL | RESEARCH GRANT | 3 |
| INDIANA UNIVERSITY | ||||||||
| 509 E 3RD STREET | BLOOMINGTON | IN | 474013654 | 356018940 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| INDIANA UNIVERSITY SCHOOL OF MEDICI | ||||||||
| 340 WEST 10TH STREET SUITE 6200 | INDIANAPOLIS | IN | 462023082 | 356001673 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| IUPUI | ||||||||
| 980 INDIANA AVENUE | INDIANAPOLIS | IN | 462022915 | 356001673 | $133,333 | ACCRUAL | RESEARCH GRANT | 3 |
| IWMF | ||||||||
| 6144 CLARK CENTER AVE | SARASOTA | FL | 34238 | 541784426 | $125,000 | ACCRUAL | RESEARCH GRANT | 3 |
| JOHN HOPKINS UNIVERSITY | ||||||||
| JOHNS HOSPKINS UNIVERSITY CENTRAL L | CHICAGO | IL | 60693 | 520595110 | $299,238 | FMV | RESEARCH GRANT | 3 |
| JOHNS HOPKINS UNIV | ||||||||
| 12529 COLLECTIONS CENTER DRIVE | CHICAGO | IL | 60693 | 520595110 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| JOHNS HOPKINS UNIV | ||||||||
| 12529 COLLECTIONS CENTER DRIVE | CHICAGO | IL | 60693 | 520595110 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| JOHNS HOPKINS UNIV | ||||||||
| 12529 COLLECTIONS CENTER DRIVE | CHICAGO | IL | 60693 | 520595110 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| 12529 COLLECTIONS CENTER DRIVE | CHICAGO | IL | 60693 | 520595110 | $300,000 | FMV | THERAPY ACCELERATION | 3 |
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | ||||||||
| 12529 COLLECTIONS CENTER DRIVE | CHICAGO | IL | 60693 | 520595110 | $250,000 | FMV | THERAPY ACCELERATION | 3 |
| KITE PHARMA INC | ||||||||
| 2225 COLORADO AVENUE | SANTA MONICA | CA | 90404 | 271524986 | $1,000,000 | FMV | THERAPY ACCELERATION | |
| LA JOLLA INST FOR ALLERGY & IMMUNOL | ||||||||
| 9420 ATHENA CIRCLE | LA JOLLA | CA | 92037 | 330328688 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| LELAND STANFORD JUNIOR UNIVERSITY | ||||||||
| STANFORD UNIVERSITY LOCKBOX PO BOX | SAN FRANCISCO | CA | 94144 | 941156365 | $100,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| PO BOX 414876 | BOSTON | MA | 022414876 | 041564655 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| PO BOX 414876 | BOSTON | MA | 022414876 | 041564655 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| PO BOX 414876 | BOSTON | MA | 022414876 | 041564655 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| PO BOX 414876 | BOSTON | MA | 022414876 | 041564655 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| PO BOX 414876 | BOSTON | MA | 022414876 | 041564655 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| MGH RESEARCH FINANCE PO BOX 414876 | BOSTON | MA | 02241 | 041564655 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MASSACHUSETTS INSTITUTE OF TECHNOLO | ||||||||
| 77 MASSACHUSETTS AVE | CAMBRIDGE | MA | 02139 | 042103594 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MAYO CLINIC ARIZONA | ||||||||
| MAYO CLINIC RESEARCH PO BOX 860334 | MINNEAPOLIS | MN | 554860334 | 860800150 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MAYO CLINIC ROCHESTER | ||||||||
| PO BOX 860334 | MINNEAPOLIS | MN | 554860334 | 416011702 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MAYO CLINIC ROCHESTER | ||||||||
| PO BOX 860334 | MINNEAPOLIS | MN | 554860334 | 416011702 | $300,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MAYO CLINIC ROCHESTER | ||||||||
| PO BOX 860334 | MINNEAPOLIS | MN | 554860334 | 416011702 | $329,938 | FMV | RESEARCH GRANT | 3 |
| MD ANDERSON CANCER CENTER | ||||||||
| PO BOX 4390 | HOUSTON | TX | 772104390 | 746001118 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MD ANDERSON CANCER CENTER | ||||||||
| PO BOX 4390 | HOUSTON | TX | 772104390 | 746001118 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MD ANDERSON CANCER CENTER | ||||||||
| PO BOX 4390 | HOUSTON | TX | 772104390 | 746001118 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MD ANDERSON CANCER CENTER | ||||||||
| PO BOX 4390 | HOUSTON | TX | 772104390 | 746001118 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MD ANDERSON CANCER CENTER | ||||||||
| PO BOX 4390 | HOUSTON | TX | 772104390 | 746001118 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MD ANDERSON CANCER CENTER | ||||||||
| PO BOX 4390 | HOUSTON | TX | 77210 | 746001118 | $400,000 | FMV | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $192,404 | ACCRUAL | RESEARCH GRANT | 3 |
| MEMORIAL SLOAN KETTERING CANCER CEN | ||||||||
| PO BOX 026338 | NEW YORK | NY | 10087 | 131924236 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MOFFITT CANCER CENTER | ||||||||
| PO BOX 742801 | ATLANTA | GA | 303742801 | 593238634 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| MPNRF | ||||||||
| 180 N MICHIGAN AVENUE SUITE 1870 | CHICAGO | IL | 60601 | 364330967 | $100,000 | ACCRUAL | RESEARCH GRANT | 3 |
| NEW YORK UNIVERSITY | ||||||||
| 665 BROADWAY SUITE 801 | NEW YORK | NY | 100122331 | 135562308 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| NORTHWESTERN UNIVERSITY | ||||||||
| 633 CLARK - ROOM G547 | EVANSTON | IL | 60208 | 362167817 | $133,333 | ACCRUAL | RESEARCH GRANT | 3 |
| NYU MEDICAL CENTER | ||||||||
| 1 PARK AVENUE 6TH FLOOR | NEW YORK | NY | 10016 | 135562308 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| NYU SCHOOL OF MEDICINE | ||||||||
| PO BOX 415026 | BOSTON | MA | 022414150 | 135562308 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| NYU SCHOOL OF MEDICINE | ||||||||
| PO BOX 415026 | BOSTON | MA | 022414150 | 135562308 | $1,250,000 | ACCRUAL | RESEARCH GRANT | 3 |
| NYU SCHOOL OF MEDICINE | ||||||||
| PO BOX 415026 | BOSTON | MA | 022414150 | 135562308 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| NYU SCHOOL OF MEDICINE | ||||||||
| PO BOX 415026 | BOSTON | MA | 022414150 | 135562308 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 3181 SW SAM JACKSON PARK ROAD | PORTLAND | OR | 972393098 | 237083114 | $1,111,000 | FMV | THERAPY ACCELERATION | 3 |
| OREGON HEALTH & SCIENCE UNIVERSITY | ||||||||
| 3181 SW SAM JACKSON PARK ROAD | PORTLAND | OR | 972393098 | 237083114 | $1,111,000 | FMV | THERAPY ACCELERATION | 3 |
| PENN MEDICINE | ||||||||
| 295 JOHN MORGAN BUILDING 3620 HAMI | PHILADELPHIA | PA | 19104 | 231352685 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| PRESIDENT & FELLOWS OF HARVARD COLL | ||||||||
| PO BOX 415649 | BOSTON | MA | 024415649 | 042103580 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $106,384 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $300,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $300,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $300,000 | ACCRUAL | RESEARCH GRANT | 3 |
| REGENTS OF THE UNIVERSITY OF MICHIG | ||||||||
| PO BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | $349,925 | FMV | RESEARCH GRANT | 3 |
| RESEARCH FOUNDATION SUNY | ||||||||
| 750 E ADAMS STREET ROOM 209 CAB | SYRACUSE | NY | 13210 | 141368361 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ST JUDE CHILDREN'S RESEARCH HOSPIT | ||||||||
| PO BOX 1000 DEPT 949 | MEMPHIS | TN | 381480949 | 620646012 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| ST JUDE CHILDREN'S RESEARCH HOSPIT | ||||||||
| PO BOX 1000 DEPT 949 | MEMPHIS | TN | 381480949 | 620646012 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| STANFORD UNIVERSITY | ||||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 941444253 | 941156365 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| STANFORD UNIVERSITY | ||||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 941444253 | 941156365 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| STANFORD UNIVERSITY | ||||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 941444253 | 941156365 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| STANFORD UNIVERSITY | ||||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 941444253 | 941156365 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| STANFORD UNIVERSITY | ||||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 941444253 | 941156365 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| STEMLINE THERAPEUTICS INC | ||||||||
| 750 LEXINGTON AVENUE 11TH FLOOR | NEW YORK | NY | 10022 | 450522567 | $500,000 | FMV | THERAPY ACCELERATION | |
| TEMPLE UNIVERSITY | ||||||||
| PO BOX 824242 | PHILADELPHIA | PA | 191824242 | 231365971 | $400,000 | FMV | RESEARCH GRANT | 3 |
| THE OHIO STATE UNIVERSITY | ||||||||
| 1960 KENNY ROAD | COLUMBUS | OH | 43210 | 316025986 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| THE OHIO STATE UNIVERSITY | ||||||||
| 1960 KENNY ROAD OFFICE OF SPONSORE | COLUMBUS | OH | 43210 | 316025986 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| THE SCRIPPS RESEARCH INSTITUTE | ||||||||
| 10550 NORTH TORREY PINES ROAD TPC- | LA JOLLA | CA | 92037 | 330435954 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| THE UNIVERSITY OF ARIZONA | ||||||||
| 512 PO BOX 210066 | TUCSON | AZ | 857210066 | 742652689 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 6030 S ELLIS AVE ROOM 114 ED-11 | CHICAGO | IL | 60637 | 362177139 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 6030 S ELLIS AVE ROOM 114 ED-11 | CHICAGO | IL | 60637 | 362177139 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 6030 S ELLIS AVE ROOM 114 ED-11 | CHICAGO | IL | 60637 | 362177139 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| THE UNIVERSITY OF CHICAGO | ||||||||
| 5841 S MARYLAND AVE MC6092 | CHICAGO | IL | 60637 | 362177139 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| TUFTS MEDICAL CENTER | ||||||||
| 800 WASHINGTON STREET 453 | BOSTON | MA | 02111 | 042103634 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UC SAN DIEGO - HEALTH SCIENCES | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 952872494 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNC AT CHAPEL HILL | ||||||||
| PO BOX 402420 | ATLANTA | GA | 303842420 | 566001393 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNC AT CHAPEL HILL | ||||||||
| PO BOX 402420 | ATLANTA | GA | 303842420 | 566001393 | $199,541 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIV OF TEXAS HEALTH SCIENCE CENTER | ||||||||
| MAIL CODE 78287703 FLOYD CURL DRIVE | SAN ANTONIO | TX | 782293900 | 741586031 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIV OF MASSACHUSETTS | ||||||||
| 55 LAKE AVENUE NORTH | WORCESTER | MA | 016550002 | 043167352 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIV OF MASSACHUSETTS | ||||||||
| 55 LAKE AVENUE NORTH | WORCESTER | MA | 016550002 | 043167352 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIV OF MASSACHUSETTS | ||||||||
| 55 LAKE AVENUE NORTH | WORCESTER | MA | 016550002 | 043167352 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIV OF MASSACHUSETTS | ||||||||
| 55 LAKE AVENUE NORTH | WORCESTER | MA | 016550002 | 043167352 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIV OF MASSACHUSETTS | ||||||||
| 55 LAKE AVENUE NORTH | WORCESTER | MA | 016550002 | 043167352 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIV OF MASSACHUSETTS | ||||||||
| 55 LAKE AVENUE NORTH | WORCESTER | MA | 016550002 | 043167352 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | ||||||||
| 1530 3RD AVENUE SOUTH SUITE 1170 | BIRMINGHAM | AL | 352940111 | 636005396 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | ||||||||
| 1530 3RD AVENUE SOUTH SUITE 1170 | BIRMINGHAM | AL | 352940111 | 636005396 | $300,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | ||||||||
| 1530 3RD AVENUE SOUTH SUITE 1170 | BIRMINGHAM | AL | 352940111 | 636005396 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | ||||||||
| 1530 3RD AVENUE SOUTH SUITE 1170 | BIRMINGHAM | AL | 352940111 | 636005396 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA LOS ANGEL | ||||||||
| 11000 KINROSS AVE SUITE 102 | LOS ANGELES | CA | 90095 | 956006143 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | $1,250,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | ||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 1855 FOLSOM STREET SUITE 425 | SAN FRANCISCO | CA | 94143 | 946036493 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 1855 FOLSOM STREET SUITE 425 | SAN FRANCISCO | CA | 94143 | 946036493 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 1855 FOLSOM STREET SUITE 425 | SAN FRANCISCO | CA | 94143 | 946036493 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 1855 FOLSOM STREET SUITE 425 | SAN FRANCISCO | CA | 94143 | 946036493 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 1855 FOLSOM STREET SUITE 425 | SAN FRANCISCO | CA | 94143 | 946036493 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 1855 FOLSOM STREET SUITE 425 | SAN FRANCISCO | CA | 94143 | 946036493 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 1855 FOLSOM STREET SUITE 425 | SAN FRANCISCO | CA | 94143 | 946036493 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| 1855 FOLSOM STREET SUITE 425 | SAN FRANCISCO | CA | 94143 | 946036493 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| CGA BOX 0897 | SAN FRANCISCO | CA | 94143 | 946036493 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| CGA BOX 0897 | SAN FRANCISCO | CA | 94143 | 946036493 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CALIFORNIA SAN FRANC | ||||||||
| CGA BOX 0897 | SAN FRANCISCO | CA | 94143 | 946036493 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF CONNECTICUT HEALTH CE | ||||||||
| 263 FARMINGTON AVENUE | FARMINGTON | CT | 060305335 | 521725543 | $150,000 | FMV | RESEARCH GRANT | |
| UNIVERSITY OF FLORIDA | ||||||||
| 33 TIGERT HALL P O BOX 113001 | GAINESVILLE | FL | 326113001 | 596002052 | $109,169 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF FLORIDA | ||||||||
| 33 TIGERT HALL P O BOX 113001 | GAINESVILLE | FL | 326113001 | 596002052 | $1,250,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF IOWA | ||||||||
| GILMORE HALL UNIVERSITY OF IOWA | IOWA CITY | IA | 52242 | 426004813 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF MARYLAND AT BALTIMORE | ||||||||
| PO BOX 41428 | BALTIMORE | MD | 212036428 | 526002033 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF MINNESOTA | ||||||||
| 450 MCNAMARA ALUMNI CENTER 200 OAK | MINNEAPOLIS | MN | 55455 | 416042488 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF MINNESOTA TWIN CITIE | ||||||||
| 450 MCNAMARA ALUMNI CENTER | MINNEAPOLIS | MN | 55455 | 416007513 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| PO BOX 785541 | PHILADELPHIA | PA | 191785541 | 231352685 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| PO BOX 785541 | PHILADELPHIA | PA | 191785541 | 231352685 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| PO BOX 785541 | PHILADELPHIA | PA | 191785541 | 231352685 | $1,250,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF PENNSYLVANIA | ||||||||
| PO BOX 785541 | PHILADELPHIA | PA | 191785541 | 231352685 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF SOUTH CAROLINA | ||||||||
| 901 SUMTER STREET 5TH FLOOR USC R | COLUMBIA | SC | 29208 | 576001153 | $25,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF SOUTHERN CALIFORNIA | ||||||||
| 2250 ALCAZAR STREET CONTRACTS GR | LOS ANGELES | CA | 900742095 | 951642394 | $65,000 | ACCRUAL | RESEARCH GRANT | 3 |
| UNIVERSITY OF TEXAS | ||||||||
| PO BOX 4390 | HOUSTON | TX | 772104390 | 300710145 | $1,000,000 | FMV | THERAPY ACCELERATION | 3 |
| UT SOUTHWESTERN MEDICAL CENTER | ||||||||
| PO BOX 841753 | DALLAS | TX | 752841753 | 756002868 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| VALOR BIOTHERAPEUTICS | ||||||||
| PO BOX 15922 | COLLEGE STATION | TX | 77841 | 461883738 | $450,000 | FMV | THERAPY ACCELERATION | |
| VALOR BIOTHERAPEUTICS | ||||||||
| PO BOX 15922 | COLLEGE STATION | TX | 77841 | 461883738 | $400,000 | FMV | THERAPY ACCELERATION | |
| VANDERBILT UNIVERSITY MEDICAL CENTE | ||||||||
| DEPT 1236 PO BOX 121236 | DALLAS | TX | 753121236 | 620476822 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| VIRGINIA COMMONWEALTH UNIVERSITY | ||||||||
| PO BOX 843039 | RICHMOND | VA | 232843039 | 012201761 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| WASHINGTON UNIVERSITY SCHOOL OF MED | ||||||||
| 700 ROSEDALE AVENUE CAMPUS BOX 1034 | ST LOUIS | MO | 631121408 | 430653611 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| WASHINGTON UNIVERSITY SCHOOL OF MED | ||||||||
| 700 ROSEDALE AVENUE CAMPUS BOX 1034 | ST LOUIS | MO | 631121408 | 430653611 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 575 LEXINGTON AVE 9TH FL | NEW YORK | NY | 10022 | 131623978 | $110,000 | ACCRUAL | RESEARCH GRANT | 3 |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 575 LEXINGTON AVE 9TH FL | NEW YORK | NY | 10022 | 131623978 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 575 LEXINGTON AVE 9TH FL | NEW YORK | NY | 10022 | 131623978 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 575 LEXINGTON AVE 9TH FL | NEW YORK | NY | 10022 | 131623978 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 575 LEXINGTON AVE 9TH FL | NEW YORK | NY | 10022 | 131623978 | $400,000 | ACCRUAL | RESEARCH GRANT | 3 |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 575 LEXINGTON AVE 9TH FL | NEW YORK | NY | 10022 | 131623978 | $390,284 | FMV | RESEARCH GRANT | 3 |
| WEILL MEDICAL COLLEGE OF CORNELL | ||||||||
| 575 LEXINGTON AVE 9TH FL | NEW YORK | NY | 10022 | 131623978 | $300,000 | FMV | THERAPY ACCELERATION | 3 |
| WHITEHEAD INSTITUTE FOR BIOMEDICAL | ||||||||
| 9 CAMBRIDGE CENTER | CAMBRIDGE | MA | 021421479 | 061043412 | $106,749 | ACCRUAL | RESEARCH GRANT | 3 |
| YALE UNIVERSITY | ||||||||
| PO BOX 208327 | NEW HAVEN | CT | 065208327 | 060646973 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| YALE UNIVERSITY | ||||||||
| PO BOX 208327 | NEW HAVEN | CT | 065208327 | 060646973 | $75,000 | ACCRUAL | RESEARCH GRANT | 3 |
| YALE UNIVERSITY | ||||||||
| PO BOX 208327 | NEW HAVEN | CT | 065208327 | 060646973 | $55,000 | ACCRUAL | RESEARCH GRANT | 3 |
| YALE UNIVERSITY | ||||||||
| PO BOX 208327 | NEW HAVEN | CT | 065208327 | 060646973 | $200,000 | ACCRUAL | RESEARCH GRANT | 3 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 84 | Total501c3OrgCnt |
| Total Other Org | 6 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (9 entries)
| Grant TypeGrantTypeTxt | RecipientRecipientCnt | Cash GrantCashGrantAmt |
|---|---|---|
| COPAY ASSISTANCE CLL | 2064 | $3,386,407 |
| COPAY ASSISTANCE LYMPHOMA | 6770 | $10,530,020 |
| COPAY ASSISTANCE MDS | 1382 | $3,097,062 |
| COPAY ASSISTANCE MYELOMA | 6191 | $20,393,154 |
| COPAY ASSISTANCE MANTEL | 647 | $1,633,028 |
| COPAY ASSISTANCE ALL | 76 | $159,372 |
| COPAY ASSISTANCE WALDENST | 443 | $1,133,194 |
| PATIENT TRAVEL ASSISTNCE | 1587 | $1,298,739 |
| PATIENT FINANCIAL AID | 260 | $12,827 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE I, PAGE 1, PART I, LINE 2 | FormAndLineReferenceDesc |
| Explanation | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (true) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | Yes (true) | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (true) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount |
|---|---|---|---|---|---|---|
| LOUIS J DEGENNARO | ||||||
| PRESIDENT & CEO | $480,095 | $30,954 | $31,500 | $23,678 | $566,227 | |
| ROSEMARIE A LOFFREDO | ||||||
| EVP - CAO & CFO | $302,398 | $22,745 | $12,775 | $13,781 | $351,699 | |
| GORDON MILLER JR | ||||||
| SVP FINANCE | $235,416 | $761 | $15,788 | $28,464 | $301,259 | $20,830 |
| MARK ROITHMAYR | ||||||
| EVP CHIEF REL OFFICE | $348,332 | $12,212 | $15,758 | $31,896 | $408,198 | |
| ANDREW S COCCARI | ||||||
| EVP CHIEF PROD OFFIC | $150,729 | $690 | $26,842 | $178,261 | ||
| CLAUDE E EDKINS | ||||||
| SVP CHIEF INFO OFFIC | $211,704 | $96,643 | $13,491 | $24,634 | $346,472 | |
| LEE M GREENBERGER | ||||||
| SVP CHIEF SCIEN OFFI | $281,965 | $6,470 | $11,351 | $31,446 | $331,232 | |
| NANCY HALLBERG | ||||||
| SVP CHIEF MARK OFFIC | $223,534 | $3,191 | $3,998 | $22,799 | $253,522 | |
| JAMES A MASSARA | ||||||
| VP APP & TRAIN. SUPP | $154,434 | $70,518 | $9,727 | $25,449 | $260,128 | |
| OSMAN MAZHAR | ||||||
| VP PLATFORM SERVICES | $151,628 | $71,893 | $9,439 | $25,255 | $258,215 | |
| JEFFREY COMO-TERM DEC2014 | ||||||
| CHIEF INFORM.OFFICER | $130,452 | $130,452 | ||||
| GEORGE J OMIROS-TERM APR15 | ||||||
| EVP-CHIEF CAMP&FIELD | $120,687 | $364,888 | $3,045 | $6,853 | $495,473 | |
| GABRIELLE URQUHART-TERM JUN15 | ||||||
| REGIONAL VP | $119,184 | $67,542 | $5,838 | $4,828 | $197,392 | |
| JOHN E WALTER - TERM FEB14 | ||||||
| PRESIDENT & CEO | $43,333 | $102,994 | $146,327 | |||
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE J, PAGE 1, PART I, LINE 4 | LOUIS J. DEGENNARO 0 1 0 JEFFREY COMO-TERM DEC2014 130,452 0 0 GEORGE J. OMIROS-TERM APR15 363,758 0 0 GABRIELLE URQUHART-TERM JUN15 66,554 0 0 JOHN E. WALTER - TERM FEB14 102,994 0 0 |
| SCHEDULE J, PAGE 1, PART I, LINE 7 | PART I, LINE 7 - NON-FIXED PAYMENTS PROVIDED BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF THE EMPLOYEE INDIVIDUAL PERFORMANCE. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B)(II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 153 | ContributionCnt |
| Noncash Contributions Rpt F990 | $1,349,813 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | MARKET VALUE | MethodOfDeterminingRevenuesTxt |
Food Inventory FoodInventoryGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 62 | ContributionCnt |
Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)
| Non Cash CheckboxNonCashCheckboxInd | DescDesc | ContributionContributionCnt |
|---|---|---|
| Yes (X) | PRINTED ITEMS | 15 |
| Yes (X) | VARIOUS | 38 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | false | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (true) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | false | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE M, PAGE 2, PART II | FormAndLineReferenceDesc |
| Explanation | PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (15 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PAGE 2, PART III, LINE 4A | WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2016, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 5 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 47 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2016, FOR THE FIFTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-TERM EFFECTS ASSOCIATED WITH STANDARD THERAPIES IN PEDIATRIC ALL AND APPLY THIS INFORMATION TO IMPROVE PATIENT OUTCOMES. THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON A |
| FORM 990, PAGE 2, PART III, LINE 4B | SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. - 615,479 FREE PRINTED DISEASE AND SUPPORT BOOKLETS, 5,498 DISEASE-FOCUSED FACT SHEETS, AND 141 DVDS WERE ORDERED IN 2016. FINANCIAL ASSISTANCE IN 2016, A COMBINED 40,835,972 WAS DISBURSED TO PATIENTS THROUGH THE CO-PAY ASSISTANCE PROGRAMS (40,029,645) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM, (793,500), AND LLS FINANCIAL ASSISTANCE PROGRAM (12,827). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2016, 40,029,645 WAS PROVIDED TO PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. - 18,155 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2016. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2016, 793,500 WAS PROVIDED TO PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM 1,587 PATIENTS RECEIVED LLS TRAVEL ASSISTANCE IN 2016 FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS (PCR PROGRAM) THE FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS SUPPORTS QUALIFYING PATIENTS WITH OUT OF POCKET EXPENSES RELATED TO THEIR ROUTINE POLYMERASE CHAIN REACTION (PCR) EXAM. IN 2016, 12,827 WAS PROVIDED TO PATIENTS THROUGH THE PCR PROGRAM 260 PATIENTS RECEIVED LLS PCR ASSISTANCE IN 2016 COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY STAFF (PATIENT ACCESS MANAGERS) AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. LOCAL PATIENT EDUCATION PROGRAMS: IN FY 2016 WE CONDUCTED 43 LOCAL PATIENT EDUCATION PROGRAMS TO 1,893 ATTENDEES. THIRTY-SIX WERE PROGRAMS THAT COVERED DISEASE SPECIFIC TOPICS, SURVIVORSHIP ISSUES, AND/OR EDUCATION ABOUT CANCER CLINICAL TRIALS AND MAKING TREATMENT DECISIONS. OF THESE 36, 12 WERE LOCATED IN AND WERE SPECIFICALLY TAILORED TO UNDERSERVED COMMUNITIES, ESPECIALLY RACIAL AND ETHNIC MINORITY GROUPS AND OLDER ADULTS. SEVEN PROGRAMS WERE FOCUSED ON THE DIAGNOSIS AND TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS OR MPN. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2016, 16 BCC CONFERENCES WERE HELD WITH 4,805 ATTENDEES LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2016, THERE WERE APPROXIMATELY 2,500 COMMUNITY MEMBERS AND 15,000 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 4,000 COMMENTS POSTED BY USERS FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2016, LLS SUPPORTED OR HOSTED 204 REGISTERED FAMILY SUPPORT GROUP MEETINGS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -717 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2016. |
| FORM 990, PAGE 2, PART III, LINE 4C | INFORMATION SPECIALISTS ALSO CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. THE INFORMATION RESOURCE CENTER ALSO HAS AN EXPANDING IN-DEPTH CLINICAL TRIAL NAVIGATION SERVICE. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2016: - 26,668 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 12,399 UNIQUE INDIVIDUALS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -167 PATIENTS WORKED WITH A CLINICAL TRIAL NAVIGATOR TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; 49% OF THESE PATIENTS ENROLLED ON A CLINICAL TRIAL. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, DISCUSSION BOARDS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. INFORMATIONAL MATERIALS ARE AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. MANY DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS ADDITIONALLY, LLS ALSO SPONSORS TELEPHONE- WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. IN FY 2016: -20,906 INDIVIDUALS PARTICIPATED IN LLS'S ONLINE DISCUSSION BOARDS -LLS PROVIDED 9 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 3,032 PARTICIPANTS -THERE WERE 24,078 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 16,612 VIEWS OF VIDEOS. |
| FORM 990, PAGE 2, PART III, LINE 4D | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. |
| FORM 990, PART V, LINE 4B | CANADA |
| FORM 990, PAGE 6, PART VI, LINE 6 | THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER. |
| FORM 990, PAGE 6, PART VI, LINE 7A | THE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS. |
| FORM 990, PAGE 6, PART VI, LINE 7B | SIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES. |
| FORM 990, PAGE 6, PART VI, LINE 11B | THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990 WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PAGE 6, PART VI, LINE 12C | ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE. |
| FORM 990, PAGE 6, PART VI, LINE 15A | THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2016 THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT- FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET AND REVIEWED THE COMPENSATION PACKAGE AND WAS DOCUMENTED AND INCLUDED IN THE COMMITTEE MINUTES. |
| FORM 990, PAGE 6, PART VI, LINE 15B | THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2016 THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT- FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET AND REVIEWED THE COMPENSATION PACKAGE AND IT WAS DOCUMENTED AND INCLUDED IN THE COMMITTEE MINUTES. |
| FORM 990, PAGE 6, PART VI, LINE 17 | ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA |
| FORM 990, PAGE 6, PART VI, LINE 19 | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. |
| FORM 990, PART XI, LINE 9 | LLS CANADA RESTATEMENT 15,601 FINANCIAL STATEMENT ROUNDING -24 TOTAL 15,577 LLS CANADA RESTATEMENT -15,601 |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp
Disregarded Entity Name DisregardedEntityName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BEAT AML LLC | BusinessNameLine1Txt |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3 INTERNATIONAL DRIVE | AddressLine1Txt |
| City | RYE BROK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10573 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Primary Activities | RESEARCH | PrimaryActivitiesTxt |
| Legal Domicile State | NY | LegalDomicileStateCd |
| Total Income | $2,158,709 | TotalIncomeAmt |
| End Of Year Assets | $2,159,709 | EndOfYearAssetsAmt |
Direct Controlling Entity Name DirectControllingEntityName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | LLS | BusinessNameLine1Txt |
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (4 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Direct Controlling NADirectControllingNACd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THE LLS RESEARCH PROGRAMS INC | ||||||||||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | 133470494 | PART VII | DE | 501C3 | 11B | LLS INC | Yes (true) | ||||||
| THE LLS RESEARCH FOUNDATION | ||||||||||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | 133709252 | PART VII | DE | 501C3 | 11B | LLS INC | Yes (true) | ||||||
| THE LLS OF CANADA | ||||||||||||||||
| PART VII | NA | false | 804 2 LANSING SQUARE | TORONTO | CA | M2J4P8 | CA | |||||||||
| PEARLPOINT CANCER SUPPORT | ||||||||||||||||
| 2817 WEST END AVENUE | NASHVILLE | TN | 37203 | 581747771 | PART VII | TN | 501C3 | 7 | Yes (true) | N/A | ||||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | false | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | false | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | false | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | false | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (true) | SharingOfFacilitiesInd |
| Paid Employees Sharing | Yes (true) | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | Yes (true) | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | Yes (true) | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp
Other Organization Name OtherOrganizationName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BEAT AML INC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Transaction Type | R | TransactionTypeTxt |
| Involved | $2,158,709 | InvolvedAmt |
| Method Of Amount Determination | COST | MethodOfAmountDeterminationTxt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE R | FormAndLineReferenceDesc |
| Explanation | THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC. THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IS THE 100% CONTROLLING MEMBER OF PEARLPOINT CANCER SUPPORT, INC. | ExplanationTxt |
Comments